Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023467 (acute myeloid leukemia)
 35,200 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 58-year-old woman with acute myelogenous leukemia in complete remission underwent successful pulmonary resection for massive hemoptysis occurring after resolution of pulmonary aspergillosis. Despite the fact that the role of surgery in the treatment of pulmonary mycosis in immunocompromised hosts is still to be clearly defined, emergency lung resections can be successfully performed in this group of patients with almost immediate recovery of stable clinical parameters. Brisk recovery can reduce overall morbidity and mortality and allow for early resumption of any necessary treatment for underlying disease.
Scand Cardiovasc J 1997
PMID:Salvage lung resection for massive hemoptysis after resolution of pulmonary aspergillosis in a patient with acute leukemia. 917 Nov 49

We reviewed 25 patients who underwent a mitral valvuloplasty, from 1984 to 1996, for mitral regurgitation (MR) associated with atrial septal defect (ASD). Mean grade of MR was 2.3 +/- 0.7. The locations of mitral valve lesion were as follows; Postero-medial side of the anterior leaflet (AML) (11 patients: 44%), posteromedial side to center of the AML (7 patients: 28%), whole of the AML (5 patients: 20%), center of the AML (1 patient: 4%), posteromedial side of the posterior leaflet (PML) (1 patient: 4%). In summary, the mitral valve lesion was located in the AML in 96% patients and were seen in the postero-medial side of 96% patients. Mitral valve repair was performed as follows; chordae shortening only (3 patients: 12%), chordae shortening + Kay's annuloplasty (9 patients: 36%), Kay's anuloplasty (10 patients: 40%), using artificial chordae only (1 patient: 4%), using artificial chordae + Kay's annuloplasty (1 patient: 4%), using artificial chordae + ring annuloplasty (1 patient: 4%). In 24 patients, the grade of MR was less than 2/4 in the early postoperative period. In one patient, the grade of 3/4 MR was still remained. Reoperation were required in 2 patients, because of gradual increase of MR, 9 years and 10 years after the initial operation, respectively. In another patient, the grade 3/4 MR recurrently occurred at 6 months after the operation. He has been well maintained medically. In all 4 patients who had more than the grade 3/4 MR postoperatively, the annuloplasty was performed with Kay's method and the cause of MR was poor coaptation around the center of the AML. The mitral valve lesion associated with ASD seemed to be the dislocation of the AML which cause the discrepancy of the coaptation zone between both leaflets, without any prominent prolapse and chordae elongation. We put a particular emphasis on that the mitral valve repair should be performed with the recognition of the etiology of the mitral valve lesion. Especially, if the lesion extends around the center of the AML, sufficient coaptation area of both leaflets at the center of the AML should be obtained by anuloplasty.
Jpn J Thorac Cardiovasc Surg 1998 Dec
PMID:[Surgical treatment for mitral regurgitation associated with secundum atrial septal defect]. 1003 43

A 54-year-old woman undergoing chemotherapy for acute myeloid leukemia developed invasive pulmonary mucormycosis in the right upper lobe at the neutropenic nadir. Amphotericin B therapy became ineffective after an abscess formed in the affected lung, and insufficient infection control compelled us to interrupt chemotherapy. The lesion was suspected of invading the anterior chest wall. After right upper lobectomy combined with the anterior chest wall resection, the chest wall defect was reconstructed using autologous free rib grafts. Successful control of the fungal infection by resection enabled us to restart chemotherapy with concomitant use of Amphotericin B. In selected cases of leukemia-associated pulmonary mucormycosis refractory to Amphotericin B therapy, aggressive surgical intervention may facilitate anti-leukemia chemotherapy and prolong survival.
Jpn J Thorac Cardiovasc Surg 2003 Apr
PMID:Pulmonary resection with chest wall removal and reconstruction for invasive pulmonary mucormycosis during antileukemia chemotherapy. 1272 89

Mediastinal granulocytic sarcoma (GS) is a relatively rare disease. We experienced a case of acute myeloid leukemia (AML) that took a rapid turn for the worse after the resection of a mediastinal GS. A healthy 60-year-old man had been in good general health all his life, but was diagnosed with a mediastinal tumor by his family physician and was referred to our department. The patient underwent resection of the mediastinal tumor because thymoma was highly suspected. On postoperative day (POD) 3, the patient suffered a fever as well as an elevated white blood cell (WBC) count and a high C-reactive protein level. His WBC count was 77,240 at its peak on POD 9, at which point the patient was diagnosed with AML by bone marrow aspiration. The immunohistological findings showed the features of leukemia, and GS was diagnosed. Despite chemotherapy, the patient died on POD 28 as a result of rapid disease progression.
Ann Thorac Cardiovasc Surg 2008 Jun
PMID:Resection of mediastinal granulocytic sarcoma triggered the rapid progression of acute myeloid leukemia. 1857 99

We report the case of an inflammatory abdominal aortic aneurysm incidentally detected clearly with diffusion-weighted magnetic resonance imaging (DW-MRI) during the examination of a patient with myelofibrosis with myeloid metaplasia that later converted to acute myeloid leukemia. DW-MRI revealed a hyperintense halo surrounding the abdominal aorta with aneurysmatic dilatation, establishing the diagnosis.
Cardiovasc Intervent Radiol 2010 Apr
PMID:Clear depiction of inflammatory abdominal aortic aneurysm with diffusion-weighted magnetic resonance imaging. 1923 83

Myelodysplastic syndromes (MDS) are acquired hematopoietic stem cell disorders characterized by ineffective hematopoiesis, cellular dysfunction and increased risks of transformation into acute myeloid leukemia. The natural history of the disease remains variable and depend upon multiple prognostic factors at the time of initial diagnosis. The current prognostic models are helpful to determine the outcome of individual patients but they remain imperfect. Earlier, the most frequent treatment given for patients with MDS was supportive with transfusion of blood products and administration of erythropoietic stimulating agents and iron chelation therapy. Now, there is an arsenal of therapies available and the landscape for the treatment of MDS is rapidly evolving. There are several FDA approved therapies available for this disorder that makes this review particularly timely and relevant.
Cardiovasc Hematol Agents Med Chem 2010 Oct 01
PMID:Update on MDS therapy: from famine to feast. 2071 77

A 39-year-old man was referred to hospital with a giant mediastinal mass, thrombocytopenia and high levels of serum tumor markers. Flow cytometry of bone marrow and peripheral blood samples led to the diagnosis of a mediastinal germ cell tumor associated with hematologic neoplasia. He was treated with combination chemotherapy for a germ cell tumor and acute myeloid leukemia. After chemotherapy, the tumor was enlarged, although serum tumor marker levels had decreased. After induction therapy, the tumor was surgically resected. This syndrome is rare, and more cases need to be studied to enable effective treatment.
Interact Cardiovasc Thorac Surg 2011 Jan
PMID:Mediastinal germ cell tumor with acute myeloid leukemia and growing teratoma syndrome. 2094 Jan 64

Living-donor lobar lung transplantation was performed in a 10-year-old boy with bronchiolitis obliterans after bone marrow transplantation for recurrent acute myeloid leukemia. He developed posterior reversible encephalopathy syndrome (PRES) due to calcineurin inhibitor (CNI) postoperatively, which was recovered with suspension of CNI. PRES should be considered one of the important morbidity after lung transplantation.
Gen Thorac Cardiovasc Surg 2012 Aug
PMID:Posterior reversible encephalopathy syndrome due to immunosuppressant after living-donor lobar lung transplantation: report of a case. 2254 27

A 16-month old boy presented with a severe tumour lysis syndrome (TLS) complicating induction therapy for acute myeloid leukaemia. This was further complicated by a respiratory syncytial virus infection. The failure of response to escalating treatment necessitated the use of extracorporeal life support (ECLS) during continuation of his induction chemotherapy. He was weaned from support after the resolution of the TLS and completed chemotherapy successfully. ECLS may have a role to play in the acute support of children with cardiorespiratory failure as a result of malignancy or the required treatment.
Interact Cardiovasc Thorac Surg 2012 Sep
PMID:Extracorporeal life support in the acute management of tumour lysis syndrome. 2264 70

Pediatric patients with Down syndrome (DS) are at an increased risk of developing certain cancers. Specifically, patients with DS have a reported 10-20-fold increased risk of developing acute myeloid leukemia (AML). Anthracycline-based treatment regimens achieve good results in patients with DS and AML. It has been proposed that DS status constitutes a risk factor for the cardiotoxicity associated with the use of anthracyclines in the pediatric setting. However, published evidence pointing toward an increased risk of cardiotoxicity in patients with DS is relatively scarce and conflictive. This concise review compiles literature relating to the incidence of anthracycline-related cardiotoxicity in pediatric patients with DS. In general, reports from trials using anthracyclines at the maximum recommended dose showed increases in the incidence of anthracycline-related cardiotoxicity in patients with DS in comparison with trials that used anthracyclines at reduced doses. Evidence from the literature suggests that patients with DS can achieve favorable therapeutic outcomes after receiving treatment with reduced doses of anthracyclines to minimize the potential for cardiotoxicity. Further prospective trials, along with the available evidence, would assist the design of treatment protocols for patients with pediatric leukemias and DS.
Cardiovasc Toxicol 2016 Jan
PMID:Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review. 2561 18


1 2 Next >>